Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules

References

• Dagan R, Poolman JT, Zepp F. Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates. Expert Rev. Vaccines7(1), 97–115 (2008).
   PubMed Web of Science ®Google Scholar
• Dagan R, Poolman J, Siegrist C. Glycoconjugate vaccines and immune interference: a review. Vaccine28, 5513–5523 (2010).
   PubMed Web of Science ®Google Scholar
• Klein Klouwenberg P, Bont L. Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines. Clin. Dev. Immunol.2008, 628963 (2008).
   PubMedGoogle Scholar
• Kitchin NRE, Southern J, Morris R et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch. Dis. Child92, 11–16 (2007).
   PubMed Web of Science ®Google Scholar
• Southern J, Crowley-Luke A, Borrow R, Andrews N, Miller E. Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine24, 215–219 (2006).
   PubMed Web of Science ®Google Scholar
• Tejedor JC, Moro M, Ruiz-Contreras J et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr. Infect. Dis. J.25, 713–720 (2006).
   PubMed Web of Science ®Google Scholar
• Schmitt H, Maechler G, Habermehl P et al. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae–Neisseria meningitidis serogroup C conjugate vaccine. Clin. Vaccine Immunol.14, 426–434 (2007).
   PubMedGoogle Scholar
• Knuf M, Szenborn L, Moro M et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr. Infect. Dis. J.28, S97–S108 (2009).
   PubMed Web of Science ®Google Scholar
• Dagan R, Eskola J, Leclerc C, Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect. Immun.66, 2093–2098 (1998).
   PubMed Web of Science ®Google Scholar
• Dagan R, Goldblatt D, Maleckar JR, Yaïch M, Eskola J. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect. Immun.72, 5383–5391 (2004).
   PubMed Web of Science ®Google Scholar
• Peeters CC, Tenbergen-Meekes AM, Poolman JT, Beurret M, Zegers BJ, Rijkers GT. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect. Immun.59, 3504–3510 (1991).
   PubMed Web of Science ®Google Scholar
• Granoff DM, Holmes SJ, Belshe RB, Osterholm MT, McHugh JE, Anderson EL. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. JAMA272, 1116–1121 (1994).
   PubMed Web of Science ®Google Scholar
• Shelly MA, Pichichero ME, Treanor JJ. Low baseline antibody level to diphtheria is associated with poor response to conjugated pneumococcal vaccine in adults. Scand. J. Infect. Dis.33, 542–544 (2001).
   PubMedGoogle Scholar
• Granoff DM, Rathore MH, Holmes SJ, Granoff PD, Lucas AH. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine11(Suppl. 1), S46–S51 (1993).
   Web of Science ®Google Scholar
• Bulkow LR, Wainwright RB, Letson GW, Chang SJ, Ward JI. Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr. Infect. Dis. J.12, 484–492 (1993).
   PubMed Web of Science ®Google Scholar
• Rennels M, King J, Ryall R, Papa T, Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr. Infect. Dis. J.23, 429–435 (2004).
   PubMed Web of Science ®Google Scholar
• Snape MD, Perrett KP, Ford KJ et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA299, 173–184 (2008).
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years. Vaccine27, 161–168 (2009).
   PubMed Web of Science ®Google Scholar
• Heath PT, McVernon J. The UK Hib vaccine experience. Arch. Dis. Child.86, 396–399 (2002).
   PubMed Web of Science ®Google Scholar
• Moss SJ, Fenton AC, Toomey J et al. Immunogenicity of a heptavalent conjugate pneumococcal vaccine administered concurrently with a combination diphtheria, tetanus, five-component acellular pertussis, inactivated polio, and Haemophilus influenzae type B vaccine and a meningococcal group C conjugate vaccine at 2, 3, and 4 months of age. Clin. Vaccine Immunol.17, 311–316 (2010).
   PubMedGoogle Scholar
• Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt H. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine24, 4727–4736 (2006).
   PubMedGoogle Scholar
• Tichmann-Schumann I, Soemantri P, Behre U et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J.24, 70–77 (2005).
   PubMed Web of Science ®Google Scholar
• Zepp F, Knuf M, Heininger UJ et al. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine22, 2226–2233 (2004).
   PubMed Web of Science ®Google Scholar
• Tichmann I, Preidel H, Grunert D et al. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine23, 3272–3279 (2005).
   PubMed Web of Science ®Google Scholar
• Reynolds D, Boisnard F, Thomas S, Mwawsi G, Grimprel E, Wysocki J. Immunogenicity and safety profile of Pediacel® compared with Infanrix®-IPV+Hib at 2,3 and 4 months of age, both co-administered with Prevenar®. Presented at: 27th Annual Meeting of the European Society for Paedatric Infectious Disease (ESPID). Brussels, Belgium, 9–13 June 2009.
   Google Scholar
• Käyhty H. Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals22, 397–402 (1994).
   PubMed Web of Science ®Google Scholar
• Käyhty H, Ahman H, Eriksson K, Sörberg M, Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr. Infect. Dis. J.24, 108–114 (2005).
   PubMed Web of Science ®Google Scholar
• Kalies H, Grote V, Siedler A, Gröndahl B, Schmitt H, von Kries R. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany’s experience after 5 years of licensure. Vaccine26, 2545–2552 (2008).
   PubMed Web of Science ®Google Scholar
• Hallander HO, Lepp T, Ljungman M, Netterlid E, Andersson M. Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease. APMIS118, 878–887 (2010).
   PubMed Web of Science ®Google Scholar
• von Kries R, Böhm O, Windfuhr A. Haemophilus influenzae b-vaccination: the urgency for timely vaccination. Eur. J. Pediatr.156, 282–287 (1997).
   PubMedGoogle Scholar
• Diez-Dominigo F, Gurtman A, Bernaola E et al. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers receiving routine vaccinations in Spain. [Abstract]. Presented at: 27th Annual Meeting of the European Society for Paedatric Infectious Disease (ESPID). Brussels, Belgium, 9–13 June 2009.
   Google Scholar
• Buttery JP, Riddell A, McVernon J et al. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA293, 1751–1758 (2005).
   PubMed Web of Science ®Google Scholar
• Griminez-Sanchez F, Kieninger D, Kueper K et al. Immunogenicity of DTaP-HBV-IPV/Hib combination vaccine antigens when given concomitantly with 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers. [abstract]. Presented at: 47th Annual Meeting of the IDSA. Philadelphia, PA, USA, 29 Ocotber–1 November 2009.
   Google Scholar
• Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics125, 866–875 (2010).
   PubMed Web of Science ®Google Scholar
• Esposito S, Tansey S, Thompson A et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin. Vaccine Immunol.17, 1017–1026 (2010).
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Ashton L et al. Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom. Pediatr. Infect. Dis. J.29, 401–405 (2010).
   PubMed Web of Science ®Google Scholar
• Olivier C, Belohradsky BH, Stojanov S, Bonnet E, Petersen G, Liese JG. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants. Vaccine26, 3142–3152 (2008).
   PubMedGoogle Scholar
• Scheifele DW, Halperin SA, Smith B, Ochnio J, Meloff K, Duarte-Monteiro D. Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2–7 months of age. Vaccine24, 2057–2064 (2006).
   PubMed Web of Science ®Google Scholar
• Pace D. MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection. Curr. Opin. Mol. Ther.11, 692–706 (2009).
   PubMedGoogle Scholar
• Knuf M, Kieninger-Baum D, Habermehl P et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine28, 744–753 (2010).
   PubMed Web of Science ®Google Scholar
• Southern J, Borrow R, Andrews N et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin. Vaccine Immunol.16, 194–199 (2009).
   PubMed Web of Science ®Google Scholar
• Arístegui J, Dal-Ré R, Díez-Delgado J et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine21, 3593–3600 (2003).
   PubMed Web of Science ®Google Scholar
• Kilpi TM, Silfverdal SA, Nilsson L et al. Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11–12 months of age. Hum. Vaccin.5, 18–25 (2009).
   PubMed Web of Science ®Google Scholar
• Silfverdal SA, Hogh B, Bergsaker MR et al. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine. Pediatr. Infect. Dis. J.28, e276–e282 (2009).
   PubMedGoogle Scholar
• Goldblatt D, Southern J, Ashton L et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J.25, 312–319 (2006).
   PubMed Web of Science ®Google Scholar